000127463 001__ 127463
000127463 005__ 20240228140929.0
000127463 0247_ $$2doi$$a10.1002/ijc.29383
000127463 0247_ $$2pmid$$apmid:25484317
000127463 0247_ $$2ISSN$$a0020-7136
000127463 0247_ $$2ISSN$$a1097-0215
000127463 0247_ $$2altmetric$$aaltmetric:2967706
000127463 037__ $$aDKFZ-2017-03486
000127463 041__ $$aeng
000127463 082__ $$a610
000127463 1001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b0$$eFirst author$$udkfz
000127463 245__ $$aEffects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: A randomized controlled trial.
000127463 260__ $$aBognor Regis$$bWiley-Liss$$c2015
000127463 3367_ $$2DRIVER$$aarticle
000127463 3367_ $$2DataCite$$aOutput Types/Journal article
000127463 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524135438_24121
000127463 3367_ $$2BibTeX$$aARTICLE
000127463 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000127463 3367_ $$00$$2EndNote$$aJournal Article
000127463 520__ $$aMultiple exercise interventions have shown beneficial effects on fatigue and quality of life (QoL) in cancer patients, but various psychosocial interventions as well. It is unclear to what extent the observed effects of exercise interventions are based on physical adaptations or rather on psychosocial factors associated with supervised, group-based programs. It needs to be determined which aspects of exercise programs are truly effective. Therefore, we aimed to investigate whether resistance exercise during chemotherapy provides benefits on fatigue and QoL beyond potential psychosocial effects of group-based interventions. One-hundred-one breast cancer patients starting chemotherapy were randomly assigned to resistance exercise (EX) or a relaxation control (RC) group. Both interventions were supervised, group-based, 2/week over 12 weeks. The primary endpoint fatigue was assessed with a 20-item multidimensional questionnaire, QoL with the EORTC QLQ-C30/BR23. Analyses of covariance for individual changes from baseline to Week 13 were calculated. In RC, total and physical fatigue worsened during chemotherapy, whereas EX showed no such impairments (between-group p = 0.098 and 0.052 overall, and p = 0.038 and 0.034 among patients without severe baseline depression). Differences regarding affective or cognitive fatigue were not significant. Benefits of EX were also seen to affect role and social function. Effect sizes were between 0.43 and 0.48. Explorative analyses indicated significant effect modification by thyroxin use (p-interaction = 0.044). In conclusion, resistance exercise appeared to mitigate physical fatigue and maintain QoL during chemotherapy beyond psychosocial effects inherent to supervised group-based settings. Thus, resistance exercise could be an integral part of supportive care for breast cancer patients undergoing chemotherapy.
000127463 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000127463 588__ $$aDataset connected to CrossRef, PubMed,
000127463 7001_ $$0P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aWiskemann, Joachim$$b1$$udkfz
000127463 7001_ $$0P:(DE-He78)15701091d8a34b4e0c2714cb14fdda09$$aArmbrust, Petra$$b2$$udkfz
000127463 7001_ $$aSchneeweiss, Andreas$$b3
000127463 7001_ $$0P:(DE-HGF)0$$aUlrich, Cornelia M$$b4
000127463 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b5$$eLast author$$udkfz
000127463 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.29383$$gVol. 137, no. 2, p. 471 - 480$$n2$$p471 - 480$$tInternational journal of cancer$$v137$$x0020-7136$$y2015
000127463 909CO $$ooai:inrepo02.dkfz.de:127463$$pVDB
000127463 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000127463 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000127463 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)15701091d8a34b4e0c2714cb14fdda09$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000127463 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000127463 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000127463 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000127463 9141_ $$y2015
000127463 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000127463 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000127463 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000127463 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000127463 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2015
000127463 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000127463 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000127463 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000127463 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000127463 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000127463 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000127463 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2015
000127463 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x0
000127463 9201_ $$0I:(DE-He78)G111-20160331$$kG111$$lBewegung, Sport und Krebs$$x1
000127463 980__ $$ajournal
000127463 980__ $$aVDB
000127463 980__ $$aI:(DE-He78)G110-20160331
000127463 980__ $$aI:(DE-He78)G111-20160331
000127463 980__ $$aUNRESTRICTED